This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Neurocrine Biosciences, Inc.

Drug Names(s): NBI-98854, VMAT2, NBI98854

Description: NBI-98854 is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is primarily responsible for re-packaging and transporting monamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells, and has been shown to be useful for the treatment of various hyperkinetic movement disorders. NBI-98854 has a minimal impact on monoamines other than dopamine, which may reduce the likelihood of off target side effects. The company intends to develop the drug for tardive dyskinesia, a side effect of antipsychotics.

NBI-98854 has also been designed to provide low, sustained, plasma and brain concentrations of the active drug to minimize side effects associated with excessive dopamine depletion.

Deal Structure: Neurocrine and Mitsubishi Tanabe
In March 2015, Neurocrine announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of NBI-98854 in Japan and other select Asian markets with Mitsubishi Tanabe. Under the terms of the agreement, Neurocrine will receive an initial payment of $30 million and is eligible to receive up to $85 million in additional milestone payments associated with the development and commercialization of NBI-98854 in Asia. Upon commercialization, Neurocrine will receive royalties on product sales from Mitsubishi Tanabe territories in Asia. Neurocrine will also support Mitsubishi Tanabe's clinical efforts in developing NBI-98854 for patients suffering from the chorea associated with Huntington's disease and tardive dyskinesia.

In addition to Japan, Mitsubishi Tanabe's territory also includes China, South Korea, Philippines, Indonesia, Taiwan, Singapore, Malaysia, Thailand, and Hong...See full deal structure in Biomedtracker

Partners: Mitsubishi Tanabe Pharma Corporation

Ingrezza News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug